Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-03-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2023年度独立董事述职报告（阎丽明）
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report'. It is a detailed report by an independent director about their duties, attendance, opinions, and activities during the year 2023. The content includes descriptions of board meetings, committee participation, audit communications, and governance oversight. It is not an announcement or a brief summary but a substantive report on management and board activities. This fits best under 'Board/Management Information (MANG)' as it relates to the independent director's report on their management and governance role. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on the independent director's duties and opinions rather than full financial statements or audit results. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed content rather than a short notice. Therefore, the classification is MANG with high confidence.
2024-03-19 Chinese
2023年度独立董事述职报告（梁桐栋）
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告' which translates to '2023 Annual Independent Director's Work Report'. It is a detailed report by an independent director about their duties, attendance, opinions, and activities during the year 2023. The content includes descriptions of board meetings, committee participation, independent opinions on company matters, communication with auditors, and compliance with laws and regulations. It does not contain financial statements or audit results but focuses on the independent director's role and governance oversight. This type of document is a management or board-related report focusing on governance and director duties rather than a full annual report, audit report, or earnings release. It is not a simple announcement or certification but a substantive report on board/management information. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length (6925 characters) supports it being a full report rather than a brief announcement.
2024-03-19 Chinese
董事会关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the independence of its independent directors. It references regulatory requirements from the China Securities Regulatory Commission and provides a detailed assessment of the independence criteria for the current independent directors. The content focuses on governance and compliance with independence standards rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement. The document fits best under Board/Management Information (MANG) as it relates to board governance and director independence disclosures.
2024-03-19 Chinese
2023年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 Annual Performance Express Announcement" and contains preliminary financial data for the year 2023, including revenue, net profit, earnings per share, and asset information. It explicitly states that the data is preliminary and unaudited, with final audited data to be disclosed in the 2023 Annual Report. The document is relatively short (2528 characters) and serves as a quick financial performance update rather than a full comprehensive annual report. It does not contain full financial statements or detailed analysis typical of a 10-K or full Annual Report. This type of document is best classified as an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2023
2024-02-25 Chinese
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2024 First Extraordinary General Meeting of Shareholders" of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions on the meeting's validity. The content focuses on the announcement of voting results from a shareholders' meeting, specifically regarding the change in use of raised funds. There is no detailed financial data or comprehensive report content, but rather the official voting outcomes and procedural confirmations. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length is short (1743 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2024-01-30 Chinese
关于山西锦波生物医药股份有限公司2024年第一次临时股东大会法律意见书
Regulatory Filings
2024-01-30 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.